Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)

Blood

Volumn 114, Issue 23, 2009, Pages 4784-4791

  De Angelis, Biagio ^a,b,c   Dotti, Gianpietro ^a   Quintarelli, Concetta ^a,b,c   Huye, Leslie E ^a   Zhang, Lan ^a   Zhang, Ming ^a   Pane, Fabrizio ^b,c   Heslop, Helen E ^a   Brenner, Malcolm K ^a   Rooney, Cliona M ^a   Savoldo, Barbara ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FK 506 BINDING PROTEIN; RECOMBINANT INTERLEUKIN 2; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TACROLIMUS; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; S6 KINASE; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG MECHANISM; DRUG RESISTANCE; EPSTEIN BARR VIRUS; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADOPTIVE TRANSFER; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE SILENCING; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NONHODGKIN LYMPHOMA; PHYSIOLOGY; PROTEIN PROCESSING; RETROVIRUS; TRANSPLANTATION; VIROLOGY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, VIRAL; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, NON-HODGKIN; MICE; MICE, SCID; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; RIBOSOMAL PROTEIN S6 KINASES; RNA, MESSENGER; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TACROLIMUS; TACROLIMUS BINDING PROTEIN 1A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73449085640     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-230482     Document Type: Article

References (38)

1. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virusspecific T lymphocytes. Nat Med. 1996;2(5):551-555.
2. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549-1555.
3. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A. 1999;96(18):10391-10396.
4. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99(7):2592-2598.
5. Haque T, Taylor C, Wilkie GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation. 2001;72(8):1399-1402.
6. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360(9331):436-442.
7. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108(9):2942-2949.
8. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123-1131.
9. Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant. 2005;5(6):1415-1422.
10. Haque T, Crawford DH. The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation. Br J Haematol. 1999;106(2):309-316.
11. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002;118(3):728-740.
12. Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation. 2000;70(1):94-99.
13. Savoldo B, Goss J, Liu Z, et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001;72(6):1078-1086.
14. First MR. Tacrolimus based immunosuppression. J Nephrol. 2004;17(suppl 8):S25-S31.
15. Vanrenterghem YF. Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine? Curr Opin Nephrol Hypertens. 1999;8(6):669-674.
16. Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant. 1999;18(5):448-455.
17. Busuttil RW, Holt CD. Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Transplant Proc. 1997;29(1-2):534-538.
18. Sharma VK, Li B, Khanna A, Sehajpal PK, Suthanthiran M. Which way for drug-mediated immunosuppression? Curr Opin Immunol. 1994;6(5):784-790. (Pubitemid 24312149)
19. Xu X, Su B, Barndt RJ, et al. FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. Transplantation. 2002;73(11):1835-1838.
20. Huai Q, Kim HY, Liu Y, et al. Crystal structure of calcineurin- cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci U S A. 2002;99(19):12037-12042.
21. Ke H, Huai Q. Structures of calcineurin and its complexes with immunophilins-immunosuppressants. Biochem Biophys Res Commun. 2003;311(4):1095-1102.
22. Dotti G, Savoldo B, Pule M, et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood. 2005;105(12):4677-4684.
23. Schomber T, Kalberer CP, Wodnar-Filipowicz A, Skoda RC. Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells. Blood. 2004;103(12):4511-4513.
24. Vera J, Savoldo B, Vigouroux S, et al. T-lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature Blymphocyte derived malignant cells. Blood. 2006;108(12):3890-3897.
25. Kelly PF, Carrington J, Nathwani A, Vanin EF. RD114-pseudotyped oncoretroviral vectors: biological and physical properties. Ann N Y Acad Sci. 2001;938:262-276.
26. Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes co-expressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and anti-tumor activity in a Hodgkin's tumor model. Blood. 2009;113(25):6392-6402.
27. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric Tcell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620-2630.
28. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol. 2000;54:19-48.
29. Houssaint E, Saulquin X, Scotet E, Bonneville M. Immunodominant CD8 T cell response to Epstein-Barr virus. Biomed Pharmacother. 2001;55(7):373-380.
30. Vera JF, Hoyos V, Savoldo B, et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009;17(5):880-888.
31. Loser K, Balkow S, Higuchi T, et al. FK506 controls CD40L-induced systemic autoimmunity in mice. J Invest Dermatol. 2006;126(6):1307-1315.
32. Quintarelli C, Vera JF, Savoldo B, et al. Coexpression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007;110(8):2793-2802.
33. Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis. 2009;11(3):195-202.
34. Leen AM, Rooney CM. Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol. 2005;128(2):135-144.
35. Fischer SA. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation. 2008;86(10):1327-1339.
36. Gottschalk S, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29-44.
37. Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation. 2009;87(2):157-163.
38. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160-1166.